ADCs in HR+/HER2- mBC: Clinical Trial and Real-world Data
The HR-positive/HER2-negative treatment landscape is rapidly evolving with the introduction of novel antibody-drug conjugate (ADC) therapies for patients who have developed resistance to endocrine-based therapy. This shifting paradigm effectuates uncertainty for health care practitioners regarding ADC…